ClinicalTrials.gg
CompletedNCT00071799Updated Oct 29, 2019Results posted

A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

A Phase 3 interventional study of Azacitidine and Physician Choice in Myelodysplastic Syndromes, sponsored by Celgene. Completed at 108 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
358
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
3rd of 126
358 · median 38
Started
2003
the only one that year
Phase 3
9 of 130
1 open now
Registered
4th of 130
by date
Lead sponsor
14 of 130
Celgene

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 3rd largest by enrollment of the 126 interventional ones that give a count, is the only one that started in 2003, is one of 9 in phase 3, and was the 4th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine have improved survival compared to conventional care treatments. The study will also assess the effect of treatments on response, duration of response, and transformation to acute myeloid leukemia (AML). The study will continue for 12 months following last patient enrolled.

See study AZA PH GL 2003 CL 001 E for information about the extension to this study.

Read the detailed description

Comparison/Control Interventions offered the physician three options:

  • Best supportive care (BSC) alone,
  • Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or
  • Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).

All three options included best supportive care. Neither the experimental group (azacitidine) nor any of the comparison/control options allowed use of erythropoietin.

Duration of Intervention: Patients will be treated until death, withdrawal, unacceptable toxicity or conclusion of the study.

03

Conditions studied

  • Myelodysplastic Syndromes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of anemia with excess blasts or refractory anemia with excess blasts in transformation according to the French-American-British classification system for myelodysplastic syndromes (MDS) and a relatively high risk of acute myeloid leukemia (AML) transformation, with an International Prognostic Scoring System score of INT-2 or High.
  • Be 18 years of age or older
  • Have a of at least 3 months
  • Be unlikely to proceed to bone marrow or stem cell transplantation therapy following remission
  • Have serum levels less than or equal to 1.5 times the for the laboratory
  • Have serum glutamic-oxaloacetic transaminase () or serum glutamic-pyruvic transaminase (alanine aminotransferase) levels less than or equal to 2 times the upper limit of normal (unless these are considered to be related to transfusion-induced secondary hemosiderosis)
  • Have serum creatinine levels less than or equal to 1.5 times the upper limit of normal

Exclusion criteria

Exclusion Criteria:

  • Secondary myelodysplastic syndromes (MDS)
  • Prior treatment with azacitidine;
  • Prior history of acute myeloid leukemia (AML);
  • Malignant disease diagnosed within prior 12 months;
  • disease;
  • Hepatic tumors;
  • Radiation, chemotherapy, cytotoxic therapy for non-MDS conditions within prior 12 months;
  • Prior transplantation or cytotoxic therapy to treat MDS;
  • Serious medical illness likely to limit survival to 12 months or less;
  • Treatment with erythropoietin or myeloid growth factors during prior 21 days or androgenic hormones during prior 13 days;
  • Active , viral hepatitis type B or C;
  • Treatment with drugs during prior 30 days;
  • Within the 28-day screening period, documented red cell folate deficiency, as evidenced by red blood cell folate (not serum folate) or vitamin B12 deficiency
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
358 participants (actual)

Study arms

  • Experimental
    Azacitidine

    Study Drug plus best supportive care. Treatment with erythropoietin was not permitted

    Drug: Azacitidine

  • Active comparator
    Conventional Care

    Physician choice of low dose cytarabine (plus best supportive care), standard chemotherapy (plus best supportive care) or best supportive care (only). Treatment with erythropoietin was not permitted

    Other: Physician Choice

Interventions

  • Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.

    Also known as: AZA

  • OtherPhysician Choice

    Physician Choice was one of three options: * Best supportive care (BSC) alone, * Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or * Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle). All three options included best supportive care

    Also known as: cytarabine, anthracycline

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimates for Median Time to Death From Any Cause

    Kaplan-Meier estimates for the median months until death from any cause within the intent-to-treat population. Patients surviving at the end of the follow-up period were censored at the date of last contact. If a patient withdrew consent to follow-up or was lost to follow-up, the patient was censored as of the last date of contact.

    Time frame: Day 1 (randomization) to 42 months

  2. Summary of Subgroup Analyses for Kaplan-Meier Estimates for Time to Death From Any Cause

    Kaplan-Meier estimates for the median months until death from any cause within the intent-to-treat population. Patients surviving at the end of the follow-up period were censored at the date of last contact. If a patient withdrew consent to follow-up or was lost to follow-up, the patient was censored as of the last date of contact. Subgroups that were analyzed are age, gender, French-American-British (FAB) classification, World Health Organization (WHO) classification and International Prognostic Scoring System (IPSS) classification.

    Time frame: Day 1 (randomization) to 42 months

  3. Number of Participants Who Died

    Count of participants who died during the study

    Time frame: 42 months

Secondary outcomes

  1. Kaplan-Meier Estimate for Median Time to Transformation to Acute Myeloid Leukemia (AML) or Death From Any Cause, Whichever Occurred First

    The time to transformation to AML or death from any cause (whichever occurred first) was defined as the number of days from the date of randomization until the date of documented AML transformation or death from any cause. Patients who did not transform to AML or die were censored at the date of last follow-up.

    Time frame: Day 1 (randomization) to 42 months

  2. Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML)

    The time to transformation to AML was defined as the number of days from the date of randomization until the date of documented AML transformation, defined as a bone marrow blast count ≥ 30% independent of baseline bone marrow count. Patients who did not transform to AML were censored at the date of last follow-up or date of death.

    Time frame: Day 1 (randomization) to 42 months

  3. Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline

    Summary of dependence and independence from red blood cell (RBC) transfusion at baseline and during treatment, for patients who were dependent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.

    Time frame: Day 1 (randomization) to 42 months

  4. Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline

    Summary of dependence and independence from red blood cell (RBC) transfusion at baseline and during treatment, for patients who were independent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.

    Time frame: Day 1 (randomization) to 42 months

  5. Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline

    Summary of dependence and independence from platelet transfusion at baseline and during treatment for patients who were dependent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.

    Time frame: Day 1 (randomization) to 42 months

  6. Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline

    Summary of dependence and independence from platelet transfusion at baseline and during treatment for patients who were independent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.

    Time frame: Day 1 (randomization) to 42 months

  7. Number of Participants Considered Hematologic Responders by Investigator Determinations Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS)

    Investigator determined responses followed IWG criteria for * complete remission(CR): repeat bone marrow show \<5% myeloblasts, and peripheral blood evaluations lasting \>=2 months of hemoglobin(\>110 g/L), neutrophils(\>=1.5x10\^9/L), platelets(\>=100x10\^9/L), blasts (0%) and no dysplasia * partial remission(PR) is the same as CR for peripheral blood: bone marrow shows blasts decrease by \>=50% or a less advanced FAB classification from pretreatment * stable disease(SD) is a failure to achieve at least a partial remission, but with no evidence of progression for at least 2 months.

    Time frame: Day 1 to 42 months

  8. Number of Participants Showing Hematologic Improvement Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS) Assessed by Independent Review Committee

    IWG 2000 Criteria: Pretreatment=hemoglobin \<100g/L or RBC transfusion-dependent, platelet count \<100x10\^9/L or platelet transfusion dependent, absolute neutrophil count \<1.5x10\^9/L. Erythroid response: Major-\>20g/L increase or transfusion independent. Minor- 10-20g/L increase or \>=50% decrease in transfusion requirements. Platelet response: Major-absolute increase of \>=30x10\^9/L or platelet transfusion independence. Minor-\>=50% increase. Neutrophil response: Major-\>=100% increase or an absolute increase of \>0.5x10\^9/L. Minor-\>=100% increase and absolute increase of \<0.5x10\^9/L.

    Time frame: Day 1 to 42 months

  9. Time to Disease Progression, Relapse After Complete or Partial Remission, or Death From Any Cause

    The time to disease progression, relapse after complete or partial remission (CR, PR), or death from any cause was defined as the time from the date of randomization until the first date of documented disease progression, relapse after CR or PR, or death from any cause.

    Time frame: Day 1 (randomization) to 42 months

  10. Duration of Any Hematologic Improvement

    The duration of improvement was defined as the time from the date of hematologic improvement until the date of first documented progression or relapse after hematologic improvement or death from any cause.

    Time frame: Day 1 (randomization) to 42 months

  11. Number of Infections Per Treatment Year Requiring Intravenous Antibiotics, Antifungals or Antivirals

    The on-treatment adverse event rate of infection requiring IV antibiotics, antifungals, or antivirals per patient-years. The on-treatment period was considered the period from the date of randomization to the last treatment study visit.

    Time frame: Day 1 (randomization) to 42 months

  12. Number of Participants in Different Categories of Adverse Experiences During Core Study Period

    Patient counts for a variety of subsets of adverse experiences for the core study period (day 1 to 42 months). The individual options for Conventional Care Regimens (Best Supportive Care Only, Low-Dose Cytarabine, and Standard Chemotherapy) are presented as separate treatments.

    Time frame: Day 1 (randomization) to 42 months

07

Results

Posted Jul 5, 2010

Participant flow

Participant flow — Overall Study
MilestoneAzacitidineConventional Care
Started179179
Completed10981
Not completed7098
Withdrew: Adverse event1910
Withdrew: Protocol violation17
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject1537
Withdrew: Physician decision02
Withdrew: Lack of efficacy1118
Withdrew: Disease progression2320
Withdrew: Different central+local pathology review01
Withdrew: Not documented02

Outcome measures

PrimaryKaplan-Meier Estimates for Median Time to Death From Any Cause

Kaplan-Meier estimates for the median months until death from any cause within the intent-to-treat population. Patients surviving at the end of the follow-up period were censored at the date of last contact. If a patient withdrew consent to follow-up or was lost to follow-up, the patient was censored as of the last date of contact.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Number · months
Kaplan-Meier Estimates for Median Time to Death From Any Cause
monthsAzacitidineConventional Care
Kaplan-Meier Estimates for Median Time to Death From Any Cause24.4615.02
Statistical analysis
  • Azacitidine vs Conventional Care · Log Rank · p = 0.0001The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification.
  • Azacitidine vs Conventional Care · Regression, Cox · p = 0.0002 · Hazard ratio (hr): 0.58 · 95% CI 0.43 to 0.77Cox proportional hazards model stratified on the randomization factors of FAB and IPSS with model term of treatment.
PrimarySummary of Subgroup Analyses for Kaplan-Meier Estimates for Time to Death From Any Cause

Kaplan-Meier estimates for the median months until death from any cause within the intent-to-treat population. Patients surviving at the end of the follow-up period were censored at the date of last contact. If a patient withdrew consent to follow-up or was lost to follow-up, the patient was censored as of the last date of contact. Subgroups that were analyzed are age, gender, French-American-British (FAB) classification, World Health Organization (WHO) classification and International Prognostic Scoring System (IPSS) classification.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Number · months
Summary of Subgroup Analyses for Kaplan-Meier Estimates for Time to Death From Any Cause
monthsAzacitidineConventional Care
Age <65 years11.317.87
Age >= 65 years24.4613.87
Age >= 75 years8.926.20
Gender: Male24.4615.02
Gender: Female25.1114.85
FAB: Refractory anemia with excess blasts (RAEB)34.6615.21
FAB: RAEB in transformation17.2515.25
WHO: RAEB 111.546.72
WHO: RAEB 221.1115.02
WHO: Other (AML, CMMoL-1 and 2, indeterminate)20.4615.25
IPSS: Intermediate 234.6616.89
IPSS: High19.2114.52
Statistical analysis
  • Azacitidine vs Conventional Care · Log Rank · p = 0.3973 (The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification)
  • Azacitidine vs Conventional Care · Log Rank · p = <0.0001 (The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification)
  • Azacitidine vs Conventional Care · Log Rank · p = 0.0707 (The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification)
  • Azacitidine vs Conventional Care · Log Rank · p = 0.0042 (The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification)
  • Azacitidine vs Conventional Care · Log Rank · p = 0.0469 (The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification)
  • Azacitidine vs Conventional Care · Log Rank · p = 0.0056 (95% CI ranges are added here. Azacitidine: low range of 21.1 months and high range of 'does not exist'. Conventional Care: low range of 9.3 and high range of 21.9 months.)The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification.
  • Azacitidine vs Conventional Care · Log Rank · p = 0.0322 (The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification)
  • Azacitidine vs Conventional Care · Log Rank · p = 0.1679 (The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification)
  • Azacitidine vs Conventional Care · Log Rank · p = 0.0692 (The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification)
  • Azacitidine vs Conventional Care · Log Rank · p = 0.0017 (The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification)
  • Azacitidine vs Conventional Care · Log Rank · p = 0.1030 (95% CI ranges are added here. Azacitidine: low range of 17.1 months and high range of 'does not exist'. Conventional Care: low range of 8.7 and high range of 24.1 months.)The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification.
  • Azacitidine vs Conventional Care · Log Rank · p = 0.0020 (95% CI ranges are added here. Azacitidine: low range of 15.0 months and high range of 'does not exist'. Conventional Care: low range of 9.0 and high range of 17.0 months.)The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification
SecondaryKaplan-Meier Estimate for Median Time to Transformation to Acute Myeloid Leukemia (AML) or Death From Any Cause, Whichever Occurred First

The time to transformation to AML or death from any cause (whichever occurred first) was defined as the number of days from the date of randomization until the date of documented AML transformation or death from any cause. Patients who did not transform to AML or die were censored at the date of last follow-up.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Median · months
Kaplan-Meier Estimate for Median Time to Transformation to Acute Myeloid Leukemia (AML) or Death From Any Cause, Whichever Occurred First
monthsAzacitidineConventional Care
Kaplan-Meier Estimate for Median Time to Transformation to Acute Myeloid Leukemia (AML) or Death From Any Cause, Whichever Occurred First13.02 (9.9 to 15.0)7.61 (5.4 to 9.8)
Statistical analysis
  • Azacitidine vs Conventional Care · Log Rank · p = 0.0025 (The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification.)
  • Azacitidine vs Conventional Care · Regression, Cox · p = 0.0027 · Hazard ratio (hr): 0.68 · 95% CI 0.53 to 0.87Cox proportional hazards model stratified on the randomization factors of FAB and IPSS with model term of treatment.
SecondaryKaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML)

The time to transformation to AML was defined as the number of days from the date of randomization until the date of documented AML transformation, defined as a bone marrow blast count ≥ 30% independent of baseline bone marrow count. Patients who did not transform to AML were censored at the date of last follow-up or date of death.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Median · months
Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML)
monthsAzacitidineConventional Care
Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML)20.66 (14.9 to 25.5)15.44 (12.4 to 22.5)
Statistical analysis
  • Azacitidine vs Conventional Care · Log Rank · p = 0.2555 (The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification)
  • Azacitidine vs Conventional Care · Regression, Cox · p = 0.2562 · Hazard ratio (hr): 0.83 · 95% CI 0.60 to 1.15Cox proportional hazards model stratified on the randomization factors of FAB and IPSS with model term of treatment.
SecondarySummary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline

Summary of dependence and independence from red blood cell (RBC) transfusion at baseline and during treatment, for patients who were dependent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Number · participants
Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
participantsAzacitidineConventional Care
Baseline Dependent; On-Treatment Independent5013
Baseline Dependent; On-Treatment Dependent61101
Statistical analysis
  • Azacitidine vs Conventional Care · Fisher Exact · p = <0.0001
SecondarySummary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline

Summary of dependence and independence from red blood cell (RBC) transfusion at baseline and during treatment, for patients who were independent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Number · participants
Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline
participantsAzacitidineConventional Care
Baseline Independent; On-Treatment Independent5837
Baseline Independent; On-Treatment Dependent1028
Statistical analysis
  • Azacitidine vs Conventional Care · Fisher Exact · p = 0.0005
SecondarySummary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline

Summary of dependence and independence from platelet transfusion at baseline and during treatment for patients who were dependent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Number · participants
Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
participantsAzacitidineConventional Care
Baseline Dependent; On-Treatment Independent1611
Baseline Dependent; On-Treatment Dependent2216
Statistical analysis
  • Azacitidine vs Conventional Care · Fisher Exact · p = 1.000
SecondarySummary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline

Summary of dependence and independence from platelet transfusion at baseline and during treatment for patients who were independent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Number · participants
Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline
participantsAzacitidineConventional Care
Baseline Independent; On-Treatment Independent126102
Baseline Independent; On-Treatment Dependent1550
Statistical analysis
  • Azacitidine vs Conventional Care · Fisher Exact · p = <0.0001
SecondaryNumber of Participants Considered Hematologic Responders by Investigator Determinations Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS)

Investigator determined responses followed IWG criteria for * complete remission(CR): repeat bone marrow show \<5% myeloblasts, and peripheral blood evaluations lasting \>=2 months of hemoglobin(\>110 g/L), neutrophils(\>=1.5x10\^9/L), platelets(\>=100x10\^9/L), blasts (0%) and no dysplasia * partial remission(PR) is the same as CR for peripheral blood: bone marrow shows blasts decrease by \>=50% or a less advanced FAB classification from pretreatment * stable disease(SD) is a failure to achieve at least a partial remission, but with no evidence of progression for at least 2 months.

Time frame:
Day 1 to 42 months
Reported as:
Number · participants
Number of Participants Considered Hematologic Responders by Investigator Determinations Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS)
participantsAzacitidineConventional Care
Overall (Complete + Partial Remission)5121
Complete Remission3014
Partial Remission217
Stable Disease7565
Statistical analysis
  • Azacitidine vs Conventional Care · Fisher Exact · p = 0.0001
  • Azacitidine vs Conventional Care · Fisher Exact · p = 0.0150
  • Azacitidine vs Conventional Care · Fisher Exact · p = 0.0094
  • Azacitidine vs Conventional Care · Fisher Exact · p = 0.3297
SecondaryNumber of Participants Showing Hematologic Improvement Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS) Assessed by Independent Review Committee

IWG 2000 Criteria: Pretreatment=hemoglobin \<100g/L or RBC transfusion-dependent, platelet count \<100x10\^9/L or platelet transfusion dependent, absolute neutrophil count \<1.5x10\^9/L. Erythroid response: Major-\>20g/L increase or transfusion independent. Minor- 10-20g/L increase or \>=50% decrease in transfusion requirements. Platelet response: Major-absolute increase of \>=30x10\^9/L or platelet transfusion independence. Minor-\>=50% increase. Neutrophil response: Major-\>=100% increase or an absolute increase of \>0.5x10\^9/L. Minor-\>=100% increase and absolute increase of \<0.5x10\^9/L.

Time frame:
Day 1 to 42 months
Reported as:
Number · participants
Number of Participants Showing Hematologic Improvement Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS) Assessed by Independent Review Committee
participantsAzacitidineConventional Care
Any Improvement n=177, 1788751
Erythroid Response - Major n=157, 1606217
Erythroid Response - Minor n=157, 16021
Platelet Response - Major n=141, 1294618
Platelet Response - Minor n=138, 12764
Neutrophil Response - Major n=131, 1112520
Neutrophil Response - Minor n=131, 11159
Statistical analysis
  • Azacitidine vs Conventional Care · Fisher Exact · p = <0.0001
  • Azacitidine vs Conventional Care · Fisher Exact · p = <0.0001
  • Azacitidine vs Conventional Care · Fisher Exact · p = 0.6203
  • Azacitidine vs Conventional Care · Fisher Exact · p = 0.0003
  • Azacitidine vs Conventional Care · Fisher Exact · p = 0.7514
  • Azacitidine vs Conventional Care · Fisher Exact · p = 0.8695
  • Azacitidine vs Conventional Care · Fisher Exact · p = 0.1760
SecondaryTime to Disease Progression, Relapse After Complete or Partial Remission, or Death From Any Cause

The time to disease progression, relapse after complete or partial remission (CR, PR), or death from any cause was defined as the time from the date of randomization until the first date of documented disease progression, relapse after CR or PR, or death from any cause.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Median · months
Time to Disease Progression, Relapse After Complete or Partial Remission, or Death From Any Cause
monthsAzacitidineConventional Care
Time to Disease Progression, Relapse After Complete or Partial Remission, or Death From Any Cause14.13 (9.5 to 27.6)8.82 (6.4 to 12.4)
Statistical analysis
  • Azacitidine vs Conventional Care · Log Rank · p = 0.0466 (The p value is two-sided from the log rank test which compares whether the azacitidine and control group follow the same duration curve.)
  • Azacitidine vs Conventional Care · Regression, Cox · p = 0.0474 · Hazard ratio (hr): 0.73 · 95% CI 0.53 to 1.00
SecondaryDuration of Any Hematologic Improvement

The duration of improvement was defined as the time from the date of hematologic improvement until the date of first documented progression or relapse after hematologic improvement or death from any cause.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Median · months
Duration of Any Hematologic Improvement
monthsAzacitidineConventional Care
Duration of Any Hematologic Improvement13.57 (10.1 to 16.3)5.18 (4.1 to 9.7)
Statistical analysis
  • Azacitidine vs Conventional Care · Log Rank · p = 0.0002 (The p value is two-sided from the log rank test which compares whether the azacitidine and control group follow the same duration curve.)
SecondaryNumber of Infections Per Treatment Year Requiring Intravenous Antibiotics, Antifungals or Antivirals

The on-treatment adverse event rate of infection requiring IV antibiotics, antifungals, or antivirals per patient-years. The on-treatment period was considered the period from the date of randomization to the last treatment study visit.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Number · infections per treatment year
Number of Infections Per Treatment Year Requiring Intravenous Antibiotics, Antifungals or Antivirals
infections per treatment yearAzacitidineConventional Care
Number of Infections Per Treatment Year Requiring Intravenous Antibiotics, Antifungals or Antivirals0.160.24
Statistical analysis
  • Azacitidine vs Conventional Care · exact binomial · p = 0.1327 · Risk ratio (rr): 0.67 · 95% CI 0.35 to 1.20
SecondaryNumber of Participants in Different Categories of Adverse Experiences During Core Study Period

Patient counts for a variety of subsets of adverse experiences for the core study period (day 1 to 42 months). The individual options for Conventional Care Regimens (Best Supportive Care Only, Low-Dose Cytarabine, and Standard Chemotherapy) are presented as separate treatments.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Number · participants
Number of Participants in Different Categories of Adverse Experiences During Core Study Period
participantsAzacitidineBest Supportive Care OnlyLow-dose CytarabineStandard Chemotherapy
Patients with >=1 treatment emergent AE (TEAE)175974419
Patients with >=1 treatment related TEAE16913419
Patients with >=1 serious TEAE114712714
Patients with >=1 serious treatment related TEAE4301313
Patients w TEAE leading to discontinued treatment22462
Patients w TEAE leading to dose reduction20020
Patients w TEAE leading to dose interruption820120
Post-hocKaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML) Based on the Last Bone Marrow Assessment

A sensitivity analysis of time to transformation to AML during the entire study was performed based on the last bone marrow assessment. Patients were censored based on the last bone marrow assessment.

Time frame:
Day 1 (randomization) to 42 months
Reported as:
Median · months
Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML) Based on the Last Bone Marrow Assessment
monthsAzacitidineConventional Care
Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML) Based on the Last Bone Marrow Assessment17.80 (13.6 to 23.6)11.48 (8.3 to 14.5)
Statistical analysis
  • Azacitidine vs Conventional Care · Log Rank · p = <0.0001 (The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification)
  • Azacitidine vs Conventional Care · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.50 · 95% CI 0.35 to 0.70Cox proportional hazards model stratified on the randomization factors of FAB and IPSS with model term of treatment.
PrimaryNumber of Participants Who Died

Count of participants who died during the study

Time frame:
42 months
Reported as:
Number · participants
Number of Participants Who Died
participantsAzacitidineConventional Care
Number of Participants Who Died82113

Adverse events

Collected over Treatment-emergent AEs for the 'core study' from Day 1 to 42 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azacitidine—114/175 (65.1%)175/175 (100%)
Best Supportive Care Only—71/102 (69.6%)86/102 (84.3%)
Low-dose Cytarabine—27/44 (61.4%)44/44 (100%)
Standard Chemotherapy—14/19 (73.7%)19/19 (100%)
Most frequent serious events
Showing 10 of 209
Most frequent serious events
EventAzacitidineBest Supportive Care OnlyLow-dose CytarabineStandard Chemotherapy
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)30/17535/1026/441/19
Febrile neutropeniaBlood and lymphatic system disorders19/1753/1021/445/19
PneumoniaInfections and infestations20/17512/1022/443/19
PyrexiaGeneral disorders10/1753/1025/440/19
Neutropenic colitisGastrointestinal disorders0/1750/1020/442/19
BacteraemiaInfections and infestations2/1750/1020/442/19
Neutropenic sepsisInfections and infestations4/1751/1021/442/19
Pneumonia fungalInfections and infestations1/1750/1020/442/19
AnaemiaBlood and lymphatic system disorders12/1753/1022/440/19
Bone marrow failureBlood and lymphatic system disorders2/1750/1020/441/19
Most frequent other events
Showing 10 of 180
Most frequent other events
EventAzacitidineBest Supportive Care OnlyLow-dose CytarabineStandard Chemotherapy
ThrombocytopeniaBlood and lymphatic system disorders118/17534/10221/4413/19
NeutropeniaBlood and lymphatic system disorders114/17529/10215/4410/19
DiarrhoeaGastrointestinal disorders38/17518/10210/4412/19
AnaemiaBlood and lymphatic system disorders84/17542/10219/4411/19
PyrexiaGeneral disorders46/17516/10217/4411/19
ConstipationGastrointestinal disorders88/1758/10211/448/19
NauseaGastrointestinal disorders84/17512/10216/449/19
Injection site erythemaGeneral disorders75/1750/1020/440/19
HypokalaemiaMetabolism and nutrition disorders11/1752/1021/448/19
LeukopeniaBlood and lymphatic system disorders31/1752/1023/446/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)AzacitidineConventional CareTotal
Mean68.0 ± 7.5769.2 ± 7.8768.6 ± 7.73
Sex: Female, Male
Sex: Female, Male(Participants)AzacitidineConventional CareTotal
Female4760107
Male132119251
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)AzacitidineConventional CareTotal
Caucasian177175352
Black or African American000
Asian/Oriental235
Hispanic011
Other000
French-American-British (FAB) Classification
French-American-British (FAB) Classification(participants)AzacitidineConventional CareTotal
Refractory anemia with excess blasts (RAEB)104103207
RAEB in transformation6162123
Modified chronic myelomonocytic leukemia6511
Acute myeloid leukemia112
Myeloproliferative disease426
Indeterminate369
International Prognostic Scoring System (IPSS)
International Prognostic Scoring System (IPSS)(participants)AzacitidineConventional CareTotal
Intermediate risk level 1 (0.5-1.0)51318
Intermediate risk level 2 (1.5-2.0)7670146
High risk (2.5-3.5)8285167
Not applicable538
Indeterminate11819
World Health Organization (WHO) Classification
World Health Organization (WHO) Classification(participants)AzacitidineConventional CareTotal
Refractory anemia with excess blasts - 1141731
Refractory anemia with excess blasts - 29895193
Chronic myelomonocytic leukemia - 1 (CMMoL-1)101
Chronic myelomonocytic leukemia - 2 (CMMoL-2)10515
Acute myeloid leukemia5558113
Indeterminate145
Body Surface Area
Body Surface Area(meters squared)AzacitidineConventional CareTotal
Mean1.9 ± 0.191.8 ± 0.191.9 ± 0.19
Weight
Weight(kilograms)AzacitidineConventional CareTotal
Mean76.5 ± 14.0874.6 ± 13.5875.6 ± 13.85
08

Study locations

108 sites
  • University of Alabama School of Medicine
    Birmingham, Alabama 35294, United States
  • Indiana University Cancer Center
    Indianapolis, Indiana 46202, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Mount Sinai Medical Center
    New York, New York 10029-6574, United States
  • Case Western Reserve University
    Cleveland, Ohio 44106, United States
  • Oregon Cancer Center
    Portland, Oregon 97201, United States
  • Western Pennsylvania Cancer Institute
    Pittsburgh, Pennsylvania 15224, United States
  • Froedtert Memorial Lutheran Hospital
    Milwaukee, Wisconsin 53226, United States
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Royal North Shore Hospital
    St. Leonards, New South Wales 2065, Australia
  • The Newcastle Mater Miseriecordiae Hospital
    Warratah, New South Wales 2298, Australia
  • Royal Brisbane Hospital
    Hersten, Queensland 4029, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Peter MacCallum Cancer Institute
    East Melbourne, Victoria 3002, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria 3050, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3181, Australia
  • The Royal Perth Hospital
    Perth, Western Australia 6847, Australia
  • First Clinical Base - Clinic of Hematology, MHAT - Pleven
    Pleven, 5800, Bulgaria
  • MHAT "St George" Clinic of Hematology, Plovdiv
    Plovdiv, 4002, Bulgaria
  • III-rd Internal Department, District Dispensary for Oncology diseases with stationary(DDOncDIU)
    Plovdiv, 4004, Bulgaria
  • National Centre of Hematology and Transfusiology, Sofia
    Sofia, 1756, Bulgaria
  • Multiprofile Hospital for Active Treatment (MHAT), "St. Marina" Clinic of Hematology
    Varna, 3010, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Sveta Marina"
    Varna, 9010, Bulgaria
  • Fakultni nemocnice Brno
    Jihlavska, Brno 639 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Sokolska, Hradec Kralove 500 05, Czechia
  • Fakultni Nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Vseobecna Fakultni Nemocnice
    Praha, 2 128 08, Czechia
  • Uslav Hematologie a Krevni Transfuze
    Praha, 2 128 20, Czechia
  • Chu D'Angers
    Angers, 49033, France
  • Hopital Beaujon
    Clichy, 92110, France
  • Che De Lille
    Lille, 59037, France
  • Hospital Edouard Herriot
    Lyon, 69437, France
  • Institute Paoli Calmettes
    Marseille, 13009, France
  • Chu De Nantes
    Nantes, 44093, France
  • Hospital Saint Louis
    Paris, 75010, France
  • Hopital Cochin
    Paris, 75679, France
  • Centre Henri Becquerel
    Rouen, 76038, France
  • Chu Purpan
    Toulouse, 31059, France
  • Universitatsklinikum Benjamin Franklin
    Hindenburgdamm, Berlin D-12203, Germany
  • Universitatsklinikum Bonn
    Bonn, 53105, Germany
  • Klinikum Chemnitz gGmbH
    Chemnitz, 9113, Germany
  • Universitatsklinikum Carl Gustav Carus
    Dresden, 1307, Germany
  • St Johannes Hospital
    Duisburg, 47166, Germany
  • Heinrich-Heine University Dusseldorf
    Dusseldorf, 40225, Germany
  • University Essen
    Essen, 45147, Germany
  • Gerorg-August-Universitat Gottingen
    Gottingen, 37075, Germany
  • Allgemeines Krankenhaus St. Georg
    Hamburg, D-20099, Germany
  • Universitatsklinikum Hambur-Eppendorf
    Hamburg, D-20246, Germany
  • Universitatsklinikum Kiel II
    Kiel, D-24116, Germany
  • Universitatsklinikum Ulm
    Ulm, 89070, Germany
  • University Hospital-Attikon
    Haidari, Athens 12462, Greece
  • University General Hospital of Heraklio Voutes
    Heraklio, Crete 71110, Greece
  • District General Hospital of Athens
    Athens, 11527, Greece
  • General Hospital of Chest Disease
    Athens, 11527, Greece
  • University General Hospital of Ioannina
    Ioannina, 45500, Greece
  • University General Hospital of Patra Rio
    Patra, 26500, Greece
  • Orszagos Gyogyintezeti Kozpont
    Budapest, 1135, Hungary
  • University of Pecs, 1st Dept of Internal Medicine
    Pecs, 7624, Hungary
  • University of Szeged, 2nd Department of Internal Medicine
    Szeged, 6701, Hungary
  • Policlinico S. Orsola-Malpighi
    Bologna, 40138, Italy
  • Universita di Firenze
    Firenze, 50139, Italy
  • Ospedale San Martino
    Genova, I-16132, Italy
  • Instituto Nazionale Dei Tumori
    Milano, 20133, Italy
  • Centro Oncologico Modenese
    Modena, 41100, Italy
  • Ospedale San Eugenio
    Roma, 00144, Italy
  • Policlinico Gemelli
    Roma, 00168, Italy
  • Instituto Nazionale Tumori "Regina Elena"
    Roma, 144, Italy
  • Ospedale Casa Sollievo Della Sofferenza - Irrc
    San Giovanni Rotondo, 71013, Italy
  • Universita Degli Studi Di Sassari
    Sassari, 7100, Italy
  • VU University Medical Center Amsterdam
    Amsterdam, 1081 HV, Netherlands
  • Univ Hospital St. Radboud
    Nijmejen, Netherlands
  • Samodzielny Publiczny Szpital Kliniczny Nr 1
    Gdansk, 80-952, Poland
  • Wojewodzki Szpital Specjalistyczny
    Lodz, 93-510, Poland
  • Samodzielny Publiczny Szpital Kliniczny
    Lublin, 20081, Poland
  • Wojskowy Instytut Medyczny
    Warszawa, 00-909, Poland
  • Samodzelny Publiczny Centralny Szpital Kliniczny
    Warszawa, 02-097, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1
    Wroclaw, 50-367, Poland
  • Burdenko Central Military Clinical Hospital
    Moscow, 105299, Russian Federation
  • Blokhin Cancer Research Center
    Moscow, 115487, Russian Federation
  • Scientific Haematology Center, Moscow
    Moscow, 125167, Russian Federation
  • Institute of Haematology & Blood Transfusion
    St. Petersburg, 193024, Russian Federation
  • Pavlov State Medical University
    St. Petersburg, 197022, Russian Federation
  • Pavlov State Medical University
    St. Petersburg, 197089, Russian Federation
  • City Hospital #31
    St. Petersburg, 197110, Russian Federation
  • Hospital Santa Creu I Sant Pau
    Barcelona, 08025, Spain
  • Hospital Clinic
    Barcelona, 08036, Spain
  • Hospital Universitario Germans Trias I Pujol
    Barcelona, Spain
  • Hospital de Leon
    Leon, 24071, Spain
  • Hospital Universitario De La Princesa
    Madrid, 28006, Spain
  • Hospital Ramon Y Cajal
    Madrid, 28034, Spain
  • Hospital La Paz, Madrid
    Madrid, 28046, Spain
  • Hospital Clinico San Carlos
    Madrid, 28048, Spain
  • Hospital Son Llatzer
    Palma de Mallorca, 07198, Spain
  • Hospital Universitario Del Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario La Fe
    Valencia, 46009, Spain
  • Sahlgrenska University Hospital
    Goteborg, S-413 45, Sweden
  • Lund Universtiy Hospital
    Lund, 22185, Sweden
  • University Hospital MAS
    Malmo, S-205 02, Sweden
  • Huddinge University Hospital
    Stockholm, 14186, Sweden

Showing the first 100 of 108 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb 1;28(4):562-9. doi: 10.1200/JCO.2009.23.8329. Epub 2009 Dec 21. PubMed 20026804 ↗
  • Fenaux P, Gattermann N, Seymour JF, Hellstrom-Lindberg E, Mufti GJ, Duehrsen U, Gore SD, Ramos F, Beyne-Rauzy O, List A, McKenzie D, Backstrom J, Beach CL. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol. 2010 Apr;149(2):244-9. doi: 10.1111/j.1365-2141.2010.08082.x. Epub 2010 Feb 5. Erratum In: Br J Haematol. 2010 Jun;149(6):919. PubMed 20136825 ↗
  • Santini V, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Silverman LR, List A, Gore SD, Seymour JF, Backstrom J, Beach CL. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol. 2010 Aug;85(2):130-8. doi: 10.1111/j.1600-0609.2010.01456.x. Epub 2010 Apr 12. PubMed 20394651 ↗
  • Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellstrom-Lindberg E, Santini V, List AF, Gore SD, Backstrom J, McKenzie D, Beach CL. Effects of azacitidine compared with conventional care regimens in elderly (>/= 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2010 Dec;76(3):218-27. doi: 10.1016/j.critrevonc.2010.04.005. Epub 2010 May 6. PubMed 20451404 ↗
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21. PubMed 19230772 ↗
  • Gore SD, Fenaux P, Santini V, Bennett JM, Silverman LR, Seymour JF, Hellstrom-Lindberg E, Swern AS, Beach CL, List AF. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013 Jul;98(7):1067-72. doi: 10.3324/haematol.2012.074831. Epub 2013 Apr 12. PubMed 23585522 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2003 to primary completion in Jul 2007, 44 months.

Results were first posted in Jul 2010, 3 years after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 52. This study's 44 months is close to that.

Counting every sponsor, half of 45 studies reached it within 50 months; a quarter within 38 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2003
First posted
Nov 5, 2003
StartActual
Nov 1, 2003
Primary completionActual
Jul 1, 2007
CompletionActual
Jul 1, 2007
Results first posted
Jul 5, 2010
Last update
Oct 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00071799
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 5, 2003
Start date
Nov 1, 2003
Primary completion
Jul 1, 2007
Completion
Jul 1, 2007
Results posted
Jul 5, 2010
Last update
Oct 29, 2019

Study contacts

CL Beach
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion